designed and synthesized a series of quinazoline compounds as selective and orallybioavailable type II TRK inhibitors. Property-driven and lead optimization strategies informed by structure-activityrelationship studies led to the identification of 39, which showed higher (about 15-fold) selectivity for TRKA over AURA and AURB, as well as potent cellular activity (IC50 = 56.4 nM) against the KM12 human